N. Casadevall

发表

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Stefan N. Constantinescu, William Vainchenker, S. Constantinescu, 2005, Nature.

Mutation in TET2 in myeloid cancers.

J. Soulier, W. Vainchenker, O. Bernard, 2009, The New England journal of medicine.

Pharmacovigilance and biosimilars: considerations, needs and challenges

Thomas Felix, B. Strober, I. Edwards, 2013, Expert opinion on biological therapy.

Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney.

F. Wendling, N. Casadevall, J. D. da Silva, 1988, The Journal of clinical investigation.

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis

W. Vainchenker, M. Tulliez, C. James, 2006, Leukemia.

New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.

W. Vainchenker, C. James, J. Villeval, 2006, Seminars in thrombosis and hemostasis.

Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.

E. Pronier, E. Solary, W. Vainchenker, 2011, Blood.

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients

N. Casadevall, K. Eckardt, Ş. Ertürk, 2017, Clinical nephrology.

Epoetin-induced autoimmune pure red cell aplasia.

N. Casadevall, 2005, The hematology journal : the official journal of the European Haematology Association.

Pure red-cell aplasia due to anti-erythropoietin antibodies.

N. Casadevall, K. Eckardt, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

W. Vainchenker, N. Debili, F. Delhommeau, 2007, Blood.

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lympho-myeloid progenitor in polycythemia vera and idiopathic myelofibrosis Short title: JAK2 V617F in lympho-myeloid progenitor cells

W. Vainchenker, N. Debili, J. P. Couédic, 2006 .

Autoantibodies against erythropoietin in a patient with pure red-cell aplasia.

N. Casadevall, P. Mayeux, B. Varet, 1996, The New England journal of medicine.

Feasibility of a Multiplex Flow Cytometric Bead Immunoassay for Detection of Anti-Epoetin Alfa Antibodies

J. Ferbas, N. Casadevall, S. Swanson, 2007, Clinical and Vaccine Immunology.

The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay.

M. Daha, N. Casadevall, A. Kromminga, 2003, Journal of immunological methods.

Genesis of a new spleen focus-forming virus: possible role of MCF viruses.

C. Larsen, F. Wendling, F. Moreau-Gachelin, 1983, Virology.

Fanconi ’ s anemia Author : Doctor

E. Moustacchi, N. Casadevall, 2003 .

A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

W. Vainchenker, C. James, V. Ugo, 2005, Trends in molecular medicine.

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.

W. Vainchenker, S. Koscielny, C. James, 2007, Blood.

Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms

F. Pasquier, E. Solary, W. Vainchenker, 2020, Oncogene.

Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment

E. Solary, W. Vainchenker, J. P. Couédic, 2014, Leukemia.

families with myeloproliferative disorders Genetic and clinical implications of the Val617Phe JAK2 mutation in 72

W. Vainchenker, M. Labopin, F. Delhommeau, 2013 .

Molecular aspects of myeloproliferative neoplasms

F. Delhommeau, N. Casadevall, C. Marzac, 2010, International journal of hematology.

Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines.

W. Vainchenker, J. Villeval, N. Casadevall, 2009, Blood.

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.

S. Chevret, D. Valla, P. Fenaux, 2008, Blood.

Endogenous erythroid colony formation in patients with retinal vein occlusion.

J. Piette, N. Casadevall, M. Pâques, 2007, Ophthalmology.

Oncogenic mechanisms in myeloproliferative disorders

W. Vainchenker, C. James, F. Delhommeau, 2006, Cellular and Molecular Life Sciences CMLS.

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.

G. Thomas, C. de Toma, W. Vainchenker, 2006, Blood.

Review Oncogenic mechanisms in myeloproliferative disorders

W. Vainchenker, C. James, F. Delhommeau, 2006 .

A unique clonal JAK 2 mutation leading to constitutive signalling causes polycythaemia

S. Constantinescu, H. Raslova, R. Berger, 2005 .

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

W. Vainchenker, N. Debili, V. Ugo, 2004, Experimental hematology.

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion

N. Casadevall, Sophie Park, U. Platzbecker, 2019, Annals of Hematology.

Decreased erythropoietin responsiveness to iron deficiency anemia in the elderly

N. Casadevall, J. Andreux, J. Nafziger, 1993, American journal of hematology.

Erythrocytosis associated with IgA nephropathy

A. Neuraz, N. Casadevall, B. Knebelmann, 2021, EBioMedicine.

Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating factor (rHuG-CSF) for the treatment of myelodysplastic syndromes (MDS) on anemia, costs and quality of life: a randomized controlled trial.

A. Stamatoullas, A. Vekhoff, P. Durieux, 2004 .

Autonomous Megakaryocyte Growth in Essential Thrombocythemia and Idiopathic Myelofibrosis Is Not Related to a c-mpl Mutation or to an Autocrine Stimulation by Mpl-L

W. Vainchenker, N. Debili, F. Wendling, 1999 .

Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.

W. Vainchenker, N. Debili, F. Wendling, 1999, Blood.

Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia

S. Richard, A. Baruchel, R. Wenger, 2012, Haematologica.

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

E. Solary, W. Vainchenker, L. Knoops, 2014, Leukemia.

2007 Standards, Options, and Recommendations: Use of erythropoiesis‐stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer

I. Ray-Coquard, N. Casadevall, J. Misset, 2009, Pediatric blood & cancer.

Reassessments of ESAs for cancer treatment in the US and Europe.

J. Armitage, I. Macdougall, C. Bennett, 2010, Oncology.

Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent.

G. Mufti, I. Macdougall, N. Casadevall, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythrocytosis.

N. Casadevall, P. Bruneval, C. Lacombe, 1993, Blood.

Myelofibrosis: Experimental models and human studies

W. Vainchenker, N. Debili, J. Villeval, 1998, Stem cells.

Antibodies against rHuEPO: native and recombinant.

N. Casadevall, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Importance of biologic follow-ons: experience with EPO.

N. Casadevall, J. Rossert, 2005, Best practice & research. Clinical haematology.

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

S. Belknap, P. Yarnold, A. Nissenson, 2005, Blood.

Recommendations on haematological criteria for the diagnosis of epoetin‐induced pure red cell aplasia

J. Parker-Williams, N. Casadevall, J. Rossert, 2004, European journal of haematology.

Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?

I. Macdougall, N. Casadevall, J. Rossert, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study

I. Macdougall, N. Casadevall, K. Eckardt, 2004, The Lancet.

Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia.

N. Casadevall, J. Dupont, D. Bouscary, 1998, Leukemia research.

Erythropoietin induces the tyrosine phosphorylation of its own receptor in human erythropoietin-responsive cells.

N. Casadevall, I. Dusanter-Fourt, C. Lacombe, 1992, The Journal of biological chemistry.

Autoimmune disorders of erythropoiesis

N. Casadevall, G. Tchernia, L. Croisille, 2001, Current opinion in hematology.

Human erythropoietin gene therapy for patients with chronic renal failure.

E. Galun, N. Casadevall, E. Podjarny, 2005, Blood.

High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome

N. Casadevall, F. Picard, D. Poisson, 1993, British journal of haematology.

Immunogenicity of recombinant human proteins: causes and consequences

N. Casadevall, H. Schellekens, 2004, Journal of Neurology.

Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures.

W. Vainchenker, N. Casadevall, C. Lacombe, 1982, Blood.

Polycythaemia Vera: in Vitro Studies of Circulating Erythroid Progenitors

N. Casadevall, C. Lacombe, B. Varet, 1980, British journal of haematology.

Successful treatment of thymoma‐associated pure red cell aplasia with intravenous immunoglobulins

N. Casadevall, L. Mouthon, L. Guillevin, 2000, European journal of haematology.

Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients

D. Valla, C. Degott, N. Casadevall, 2002, Gut.

Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells

E. Pronier, W. Vainchenker, J. P. Couédic, 2010, Leukemia.

Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.

D. Valla, N. Casadevall, C. Lacombe, 1985, Annals of internal medicine.

Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.

M. Hochberg, F. Pasquier, E. Solary, 2021, Blood.

Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.

D. Colomer, D. Valla, N. Casadevall, 2017, Journal of hepatology.

Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.

D. Valla, M. Tulliez, N. Casadevall, 1988, Gastroenterology.

Comparison of flow cytometry and enzyme cytochemistry for the detection of myeloperoxydase in acute myeloid leukaemia: interests of a new positivity threshold

N. Casadevall, O. Legrand, J. Perrot, 2003, British journal of haematology.

Etiology of portal vein thrombosis in adults

D. Valla, M. Tulliez, N. Casadevall, 1988 .

Membranous obstruction of the inferior vena cava associated with a myeloproliferative disorder: a clue to membrane formation?

N. Casadevall, H. Deramond, A. Hadengue, 1989, Gastroenterology.

Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy

N. Casadevall, O. Legrand, I. Elalamy, 2005, Transfusion.

Treatment with erythropoiesis stimulating agents

N. Casadevall, 2009 .

Autoimmune Neutropenia After Kidney Transplantation: A Disregarded Entity of Posttransplant Neutropenia

N. Casadevall, O. Hermine, C. Legendre, 2014, Transplantation.

[Hashimoto's thyroiditis with intra-thyroid production of a monoclonal antithyroglobulin autoantibody].

M. Tulliez, G. Karsenty, N. Casadevall, 1986, Annales d'endocrinologie.

TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event

J. Soulier, W. Vainchenker, O. Bernard, 2008 .

Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis

D. Valla, N. Casadevall, P. Rufat, 2005, British journal of haematology.

Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors.

W. Vainchenker, N. Debili, S. Barnache, 2002, Blood.

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

H. Dombret, A. Stamatoullas, L. Mannone, 2006 .

Isodicentric/pseudoisodicentric chromosome 21 amplification in four cases of acute myelocytic leukemia or myelodysplasia.

N. Casadevall, G. Tachdjian, D. Bouscary, 2002, Cancer genetics and cytogenetics.

Factor V Leiden related Budd-Chiari syndrome

D. Valla, N. Casadevall, P. Deltenre, 2001, Gut.

Maturation Ku 812: a Pluripotent Human Cell Line with Spontaneous Erythroid Terminal

N. Debili, K. Kishi, N. Casadevall, 2005 .

Granulocyte-macrophage colony-stimulating factor and erythropoietin act competitively to induce two different programs of differentiation in the human pluripotent cell line UT-7.

W. Vainchenker, N. Casadevall, N. Komatsu, 1992, Blood.

KU 812: a pluripotent human cell line with spontaneous erythroid terminal maturation.

N. Debili, P. Romeo, K. Kishi, 1989, Blood.

Structure of the Murine Erythropoietin Receptor Complex

N. Casadevall, C. Lacombe, S. Gisselbrecht, 2001 .

Structure of the murine erythropoietin receptor complex. Characterization of the erythropoietin cross-linked proteins.

N. Casadevall, P. Mayeux, S. Chrétien, 1991, The Journal of biological chemistry.

Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia.

N. Casadevall, P. Bruneval, C. Lacombe, 1990, Blood.

Cellular mechanism of resistance to erythropoietin.

N. Casadevall, 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Contribution of D-Dimer determination in the exclusion of deep venous thrombosis in spinal cord injury patients

B. Bussel, R. Carlier, N. Casadevall, 1999, Spinal Cord.

Erythroblastic synartesis: an auto-immune dyserythropoiesis.

É. Oksenhendler, G. Flandrin, N. Casadevall, 1999, Blood.

Recovery from Pure Red Cell Aplasia Caused by Anti‐Erythropoietin Antibodies After Kidney Transplantation

N. Casadevall, R. Snanoudj, S. Beaudreuil, 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

What is antibody-mediated pure red cell aplasia (PRCA)?

N. Casadevall, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Solubilization and hydrodynamic characteristics of the erythropoietin receptor. Evidence for a multimeric complex.

N. Casadevall, C. Lacombe, P. Mayeux, 1990, European journal of biochemistry.

ERYTHROPOIETIN TREATMENT IN ANAEMIC PATIENTS ON HAEMODIALYSIS

N. Casadevall, J. Zingraff, F. Peterlongo, 1986, The Lancet.

N. Casadevall, L. Coulombel, G. Tchernia, 1994, British journal of haematology.

Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes.

N. Casadevall, 1998, Seminars in oncology.

Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies

F. Pasquier, E. Solary, W. Vainchenker, 2015, Nature Genetics.

Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera.

N. Casadevall, D. Bouscary, F. Viguié, 1999, Leukemia & lymphoma.

Purification and biological activity of a recombinant human erythropoietin produced by lymphoblastoid cells.

J. L. Le Caer, N. Casadevall, C. Craescu, 1994, Preparative biochemistry.

Preparation and biological properties of monoclonal antibodies against human erythropoietin.

N. Casadevall, P. Mayeux, J. Cartron, 1993, Hybridoma.

Erythropoietin: physiology and clinical experience.

N. Casadevall, C. Lacombe, B. Varet, 1990, Seminars in hematology.

Autoimmune anemia in macaques following erythropoietin gene therapy.

R. Samulski, N. Casadevall, T. Larcher, 2004, Blood.

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

Patrick Mayeux, V. Ugo, N. Casadevall, 2002, The New England journal of medicine.

Erythroid progenitors in adult chronic pure red cell aplasia: relationship of in vitro erythroid colonies to therapeutic response.

N. Casadevall, C. Lacombe, B. Varet, 1984, Blood.

Polycythemia and steroid overproduction in a gonadotropin‐secreting seminoma of the testis

N. Casadevall, X. Troussard, C. Lacombe, 1991 .

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Stefan N Constantinescu, William Vainchenker, S. Constantinescu, 2005, Nature.

Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)

Antonio Santoro, Francesco Locatelli, A. Santoro, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Epoetin‐associated pure red cell aplasia: past, present, and future considerations

Allen R Nissenson, Dennis W Raisch, A. Nissenson, 2008, Transfusion.

JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms

E. Solary, W. Vainchenker, N. Debili, 2012, Oncogene.

Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease.

D. Labie, N. Casadevall, J. Elion, 1994, Nouvelle revue francaise d'hematologie.

Erythroid progenitors in polycythemia vera.

N. Casadevall, C. Lacombe, B. Varet, 1981, Blood cells.

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.

I. Macdougall, N. Casadevall, W. Hörl, 2012, Kidney international.

Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity

Robert Fischer, N. Casadevall, O. Hainzl, 2011, Pharmaceutical Research.

Evaluation of Methods to Detect and Characterize Antibodies against Recombinant Human Erythropoietin

Steven J. Swanson, John Ferbas, Patrick Mayeux, 2004, Nephron Clinical Practice.

Role of tyrosine kinases and phosphatases in polycythemia vera.

W. Vainchenker, Z. Zhao, N. Casadevall, 2005, Seminars in hematology.

Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro.

W. Vainchenker, J. Villeval, N. Casadevall, 1991, The Journal of clinical investigation.

Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors

D. Valla, N. Casadevall, S. Erlinger, 2000, Hepatology.

Superior mesenteric vein thrombosis as a manifestation of a latent myeloproliferative disorder.

N. Casadevall, F. Iglicki, J. Capron, 1991, Journal of clinical gastroenterology.

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.

H. Dombret, M. Dennis, P. Fenaux, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pure red-cell aplasia and epoetin therapy.

Allen R Nissenson, Stefano Luminari, Benjamin Kim, 2004, The New England journal of medicine.

Erythropoietin: sites of synthesis and regulation of secretion.

N. Casadevall, P. Bruneval, C. Lacombe, 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis

F. Pasquier, W. Vainchenker, H. Raslova, 2017, Haematologica.

Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases

J. Palmblad, S. Rives, S. Richard, 2014, Human mutation.

A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene

V. Ugo, N. Casadevall, H. Wajcman, 2008, Haematologica.

Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies.

W. Vainchenker, J. Villeval, N. Casadevall, 1996, Blood.

New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia

F. Pasquier, W. Vainchenker, H. Raslova, 2016 .

Production of erythropoietin-like activity by a murine erythroleukemia cell line.

F. Wendling, N. Casadevall, C. Lacombe, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Severe chronic primary neutropenia in adults: report on a series of 108 patients.

É. Oksenhendler, P. Moreau, C. Bellanné-Chantelot, 2015, Blood.

Cloning of human purine-nucleoside phosphorylase cDNA sequences by complementation in Escherichia coli (polysome immunoadsorption/cDNA cloning/phenotypic expression/genetic disease/immunodeficiency)

F. Wendling, S. Levene, N. Casadevall, 2022 .

Erythropoietin Production and Erythropoietin Receptors on Murine Erythroleukemic Cell Lines

N. Casadevall, C. Lacombe, E. Goldwasser, 1987 .

Erythroid cultures and erythropoietin assay. Clinical and diagnostic value.

N. Casadevall, C. Lacombe, B. Varet, 1990, Nouvelle revue francaise d'hematologie.

Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement?

N. Casadevall, A. Delmer, G. Tachdjian, 2005, Leukemia.

Erythropoiesis abnormalities contribute to early-onset anemia in patients with septic shock.

J. Chiche, J. Dhainaut, N. Casadevall, 2006, American journal of respiratory and critical care medicine.

Pure red cell aplasia induced by erythropoiesis-stimulating agents.

I. Macdougall, N. Casadevall, W. Hörl, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.

N. Casadevall, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

I. Macdougall, N. Casadevall, K. Eckardt, 2009, The New England journal of medicine.

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score.

N. Casadevall, O. Legrand, R. Zittoun, 2000, Blood.

Risk of pure red cell aplasia in patients with hepatitis C receiving antiviral therapy and an erythropoiesis-stimulating agent.

N. Casadevall, J. Rossert, D. Mytych, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Aluminium intoxication in the rat induces partial resistance to the effect of recombinant human erythropoietin.

N. Casadevall, J. Zingraff, P. Ureña, 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

N. Casadevall, J. Rossert, D. Kemeny, 2005, Kidney international.

Multimeric structure of the membrane erythropoietin receptor of murine erythroleukemia cells (Friend cells). Cross-linking of erythropoietin with the spleen focus-forming virus envelope protein.

N. Casadevall, C. Lacombe, P. Mayeux, 1991, The Journal of biological chemistry.

Budd-Chiari syndrome associated with 5q deletion and hypereosinophilia.

D. Valla, N. Casadevall, F. Viguié, 1996, Journal of clinical gastroenterology.

Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia

N. Casadevall, O. Legrand, A. Faussat, 2006, Clinical Cancer Research.

Flt 3 InternalTandem Duplication and P-Glycoprotein Functionality in 171 Patients with AcuteMyeloid Leukemia

N. Casadevall, O. Legrand, A. Faussat, 2006 .

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

P. Schatz, N. Casadevall, K. Woodburn, 2007, Experimental hematology.

Anti-erythropoietin antibodies and pure red cell aplasia.

Kai-Uwe Eckardt, N. Casadevall, K. Eckardt, 2004, Journal of the American Society of Nephrology : JASN.

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

W. Vainchenker, N. Debili, R. Favier, 2016, Blood.

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.

H. Dombret, A. Stamatoullas, A. Vekhoff, 2004, Blood.

Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity

I. Macdougall, N. Casadevall, O. Hainzl, 2011, Pharmaceutical Research.

A case of drug-induced hematotoxicity: from in vivo to in vitro assessment

N. Casadevall, F. Goldfain-Blanc, N. Claude, 2005, Comparative Clinical Pathology.

Serum Replacement in Culture of Human Erythroid and Megakaryocytic Precursors

W. Vainchenker, N. Casadevall, C. Lacombe, 1983 .

[Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance].

N. Casadevall, P. Mayeux, B. Virón, 2002, Nephrologie.

Anorexia nervosa and gelatinous transformation of bone marrow.

N. Casadevall, B. Wyplosz, D. Sicard, 1994, Nouvelle revue francaise d'hematologie.

Immune-mediated pure red cell aplasia in renal transplant recipients

N. Casadevall, E. Thervet, C. Legendre, 2008, Haematologica.

Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs.

N. Casadevall, B. Virón, A. Kolta, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Glycosylation of the murine erythropoietin receptor

N. Casadevall, C. Lacombe, P. Mayeux, 1990, FEBS letters.

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.

Kai-Uwe Eckardt, N. Casadevall, K. Eckardt, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

N. Casadevall, H. Schellekens, R. Thorpe, 2011, Kidney international.

Treatment of anaemia with rHuEpo in patients with MDS.

N. Casadevall, 1998, Medical Oncology.

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

B. Stengel, J. Haymann, M. Metzger, 2012, Clinical journal of the American Society of Nephrology : CJASN.

CASE REPORT: Cytomegalovirus infection as a cause of acute portal vein thrombosis

D. Valla, N. Casadevall, S. Erlinger, 1997, Journal of gastroenterology and hepatology.

Similar Names for Similar Biologics

B. Strober, D. Warnock, N. Casadevall, 2014, BioDrugs.

Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options.

I. Macdougall, N. Casadevall, J. Rossert, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

X. Mariette, N. Casadevall, V. Soumelis, 2007, Haematologica.

N. Casadevall, O. Legrand, D. Bouscary, 2000, British journal of haematology.

Similar Names for Similar Biologics

B. Strober, D. Warnock, N. Casadevall, 2014, BioDrugs.

[Association of autoimmune chronic active hepatitis and acquired erythroblastopenia cured by cyclophosphamide].

N. Casadevall, C. Lacombe, J. Trinchet, 1986, Gastroenterologie clinique et biologique.

[Association of chronic lymphoid leukemia and erythroblastopenia and myasthenia].

N. Casadevall, M. Davin, F. Picard, 1991, Annales de medecine interne.

1050. Autoimmune Anemia in Macaques Following Erythropoietin Gene Therapy

N. Casadevall, T. Larcher, J. Rabinowitz, 2004 .

[Standards, options and recommendations for the use of recombinant erythropoietin (epoietin alpha and beta darbepoietin-alpha, EPO) in the management of anaemia in oncology for patient undergoing radiotherapy-update 2003].